The drug maker is paying $550 million, or `3,650 crore, to buy two US-based generic companies owned by the promoters of Hetero Drugs Ltd
The drug maker is paying $550 million, or `3,650 crore, to buy two US-based generic companies owned by the promoters of Hetero Drugs Ltd
Share this Article
Recommended